COVID19

Actelis Networks Reports Second Quarter 2023

Retrieved on: 
Thursday, August 24, 2023

FREMONT, Calif., Aug. 24, 2023 (GLOBE NEWSWIRE) -- Actelis Networks, Inc. (NASDAQ: ASNS) (“Actelis” or the “Company”), a market leader in cyber-hardened, rapid deployment networking solutions for wide area IoT applications, today reported financial results for the fiscal second quarter and first six months ended June 30, 2023.

Key Points: 
  • FREMONT, Calif., Aug. 24, 2023 (GLOBE NEWSWIRE) -- Actelis Networks, Inc. (NASDAQ: ASNS) (“Actelis” or the “Company”), a market leader in cyber-hardened, rapid deployment networking solutions for wide area IoT applications, today reported financial results for the fiscal second quarter and first six months ended June 30, 2023.
  • Second Quarter and First Half 2023 Financial Highlights:
    Revenues up 3% sequentially to $1.9 million for the second quarter ended June 30, 2023, due to improved supply chain availability, and open order backlog delivery, as components availability is improving.
  • This reduction in telecom business includes a reduction in software license revenues in the second quarter of 2022 affecting such trend.
  • Fiscal Second Quarter and First Half 2023 Financial Results:
    Revenues for the for the three months ended June 30, 2023, amounted to $1.9 million, compared to $3.1 million for the three months ended June 30, 2022.

Therapeutic Solutions International Subsidiary Allogen Biologics Inc. Successfully Manufactures JadiCell Master Cell Bank to Provide Cells for Right to Try Use and Phase III ARDS Clinical Trial

Retrieved on: 
Wednesday, August 16, 2023

Therapeutic Solutions International, Inc. (TSOI), reported today successfully generation of a quality control tested Master Cell Bank comprised of its JadiCell universal donor stem cell product.

Key Points: 
  • Therapeutic Solutions International, Inc. (TSOI), reported today successfully generation of a quality control tested Master Cell Bank comprised of its JadiCell universal donor stem cell product.
  • The recently generated cells possessed both functional and phenotypic characteristics that the FDA has agreed to in its clearance of the Company to conduct a Phase III clinical trial.
  • Previously the JadiCells have demonstrated 100% reduction in lethality in COVID19 patients under 85 years old in a double-blind Phase I/II clinical trial1.
  • The quality of work conducted by his team is second to none,” said Timothy Dixon, President and CEO of Therapeutic Solutions International.

MyInnerGenius Named 2023 Globee Award Winner in the Artificial Intelligence Category

Retrieved on: 
Wednesday, June 14, 2023

NAPLES, Fla., June 14, 2023 /PRNewswire-PRWeb/ -- MyInnerGenius, a leading innovator in talent development and management, is proud to be recognized as a winner of the 2023 Globee Award for Artificial Intelligence. MyInnerGenius is an award-winning workforce and talent planning innovation that reveals people's skills and capabilities, including those that don't show up on resumes, diplomas and performance reviews. In less than 30 minutes, MyInnerGenius can reveal the micro-level skills and capabilities for an entire organization. It then creates a database which can fuel AI systems to enable laser-focused workforce planning, from selection and development to career and succession planning. MyInnerGenius is used by enterprises and educational institutions to reduce turnover, increase productivity and improve hiring diversity. To date, MyInnerGenius has administered three million assessments around the globe.

Key Points: 
  • MyInnerGenius, a workforce and talent planning innovation, announced it has been awarded a 2023 Globee Information Technology Award in the Artificial Intelligence category.
  • NAPLES, Fla., June 14, 2023 /PRNewswire-PRWeb/ -- MyInnerGenius , a leading innovator in talent development and management, is proud to be recognized as a winner of the 2023 Globee Award for Artificial Intelligence.
  • In less than 30 minutes, MyInnerGenius can reveal the micro-level skills and capabilities for an entire organization.
  • And most career starters and career changers have no idea what they were born to do," Denise Leaser, President of MyInnerGenius, said.

InventHelp Inventor Develops Improved Automatic Aerosol Disinfectant (CSK-372)

Retrieved on: 
Tuesday, June 13, 2023

This compact and lightweight device could be used to help prevent the spread of viruses such as Coronavirus and the Flu.

Key Points: 
  • This compact and lightweight device could be used to help prevent the spread of viruses such as Coronavirus and the Flu.
  • In doing so, it would improve and sanitize working and living conditions by fulfilling the need for a means to sanitize large areas quickly.
  • The original design was submitted to the Grain Valley sales office of InventHelp.
  • 21-CSK-372, InventHelp, 217 Ninth Street, Pittsburgh, PA 15222, or call (412) 288-1300 ext.

Inotrem Announces Publication of Two Key Articles on Nangibotide Phase II Programs in Peer-reviewed Medical Journals

Retrieved on: 
Thursday, June 1, 2023

The first article presents the ASTONISH Phase 2b trial in septic shock patients and the second one the ESSENTIAL Phase 2 trial for the treatment of critically ill COVID-19 patients.

Key Points: 
  • The first article presents the ASTONISH Phase 2b trial in septic shock patients and the second one the ESSENTIAL Phase 2 trial for the treatment of critically ill COVID-19 patients.
  • The findings presented further validate Inotrem’s innovative approach to treat inflammatory diseases by targeting TREM-1.
  • “Nangibotide is the first TREM-1 inhibitor and has the potential to become the first causal treatment of life-threatening immune dysregulations.
  • “We look forward to bringing this potential new treatment option to patients suffering from severe and often fatal inflammatory conditions.”

Star Equity Fund Launches Proxy Solicitation at Servotronics

Retrieved on: 
Tuesday, May 23, 2023

OLD GREENWICH, Conn., May 23, 2023 (GLOBE NEWSWIRE) -- Star Equity Fund, LP (“Star Equity” or “we”) is an investment fund focused on unlocking shareholder value and improving corporate governance at its portfolio companies. Star Equity owns 5.4% of the common stock of Servotronics, Inc. (NYSE American: SVT) (“Servotronics,” “SVT,” or the “Company”) and announced today it has filed its definitive proxy statement and begun soliciting proxies urging all stockholders to vote the WHITE proxy card to elect G. Mark Pomeroy and Richard K. Coleman, Jr. to the Company’s board of directors (the “Board”) at the Company’s 2023 annual meeting of shareholders (the “Annual Meeting”), which will be held in a virtual format on June 9, 2023 at 9:00 a.m., E.T.

Key Points: 
  • OLD GREENWICH, Conn., May 23, 2023 (GLOBE NEWSWIRE) -- Star Equity Fund, LP (“Star Equity” or “we”) is an investment fund focused on unlocking shareholder value and improving corporate governance at its portfolio companies.
  • Star Equity Fund, LP (“Star Equity Fund”), together with the other participants named herein (collectively, “Star Equity”), intends to file a definitive proxy statement and accompanying WHITE proxy card with the Securities and Exchange Commission (“SEC”) to be used to solicit votes for the election of its slate of highly-qualified director nominees at the 2023 annual meeting of stockholders of Servotronics, Inc., a Delaware corporation (the “Company”).
  • STAR EQUITY STRONGLY ADVISES ALL STOCKHOLDERS OF THE COMPANY TO READ THE PROXY STATEMENT AND OTHER PROXY MATERIALS AS THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION.
  • IN ADDITION, THE PARTICIPANTS IN THIS PROXY SOLICITATION WILL PROVIDE COPIES OF THE PROXY STATEMENT WITHOUT CHARGE, WHEN AVAILABLE, UPON REQUEST.

Highlights - Vote on on the updated EU Financial Regulation - Committee on Budgetary Control

Retrieved on: 
Friday, April 21, 2023

Vote on on the updated EU Financial Regulation

Key Points: 
  • Vote on on the updated EU Financial Regulation
    21-04-2023 - 11:30
    On 27 April 2023, the Committees on Budgets and on Budgetary Control will vote on the recast of the Financial rules applicable to the general budget of the Union.
  • The Financial Regulation lays down the principles and general financial rules for establishing and implementing the EU budget and controlling EU finances.
  • The recast mostly builds on the lessons learned from the COVID19 pandemic and focuses on crisis management, the protection of EU financial interests, and simplification.

A Detailed Look at Fosun International's Annual Results: Create Space to Concentrate on Core Businesses in 2022, Poised for Rebound in 2023

Retrieved on: 
Thursday, March 30, 2023

Complementing the financial figures, Guo Guangchang, Chairman of Fosun International, published a Letter to Shareholders on 29 March.

Key Points: 
  • Complementing the financial figures, Guo Guangchang, Chairman of Fosun International, published a Letter to Shareholders on 29 March.
  • In the letter, Guo Guangchang candidly responded to questions such as debt, business, and strategy that investors are highly concerned about.
  • While stepping up its efforts in the divestment of non-strategic and non-core assets, Fosun has also made continuous efforts in financing.
  • In fact, since the beginning of 2023, Fosun's businesses in consumer and tourism sectors have shown a remarkable upward trend.

TA Detailed Look at Fosun International's Annual Results: Create Space to Concentrate on Core Businesses in 2022, Poised for Rebound in 2023

Retrieved on: 
Thursday, March 30, 2023

Complementing the financial figures, Guo Guangchang, Chairman of Fosun International, published a Letter to Shareholders on 29 March.

Key Points: 
  • Complementing the financial figures, Guo Guangchang, Chairman of Fosun International, published a Letter to Shareholders on 29 March.
  • In the letter, Guo Guangchang candidly responded to questions such as debt, business, and strategy that investors are highly concerned about.
  • While stepping up its efforts in the divestment of non-strategic and non-core assets, Fosun has also made continuous efforts in financing.
  • In fact, since the beginning of 2023, Fosun's businesses in consumer and tourism sectors have shown a remarkable upward trend.

Bioxytran Announces Positive Phase 2 Trial Results were Featured in “Vaccines” a Peer-Reviewed Journal

Retrieved on: 
Wednesday, March 29, 2023

BOSTON, MASSACHUSETTS, March 29, 2023 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (BIXT), (the “Company”), a clinical stage biotechnology company developing oral drugs to treat COVID-19 and other viral diseases, announced that the journal “Vaccines” released a peer-reviewed article, “An Oral Galectin Inhibitor in COVID-19 – A Phase 2 Randomized Controlled Trial”, which contains top-line safety and efficacy results of the Company’s randomized, placebo-controlled Phase 2 clinical trial in 34 patients with mild-to-moderate COVID-19. During the 7 days of treatment, an orally administered Galectin Antagonist in the form of a chewable tablet was administered. The endpoint was a statistically significant reduction in viral load measured by the number of patients reaching a below threshold PCR value (Ct value ≥ 29) by day 7. Additionally, most of the symptoms completely disappeared in the group receiving the drug whereas the placebo group had 41.18% of patients that continued to experience chills, 29.41% that had a feverish sensation, and 35.29% that had a cough on day 7. The trial met its endpoint with a 100% response rate by day 7 versus 6% in placebo, which was statistically significant (p-value =.001).

Key Points: 
  • During the 7 days of treatment, an orally administered Galectin Antagonist in the form of a chewable tablet was administered.
  • The trial met its endpoint with a 100% response rate by day 7 versus 6% in placebo, which was statistically significant (p-value =.001).
  • Our analysis also revealed an 82% responders rate by day 3, which was statistically significant (p-value = .001).
  • The positive data from this clinical trial provided the rationale of dosing and protocol design for study in an upcoming phase 2/3 registrational trial.